ARTICLE | Company News
Ocera hepatic news
September 30, 2013 7:00 AM UTC
Ocera said it will reduce headcount by 17 through the closure of its facility in Sherbrooke, Quebec, effective Nov. 11, and will focus on lead compound ornithine phenylacetate ( OCR-002). The ammonia scavenger is in Phase II testing for Orphan liver diseases. At June 30, Ocera had $8.6 million in cash and a six-month operating loss of $5.9 million. ...